Prior authorization for FDA-approved PARP inhibitors in ovarian cancer

Prior authorization for FDA-approved PARP inhibitors in ovarian cancer

Objectives: PARP inhibitors (PARP-I) improve survival in ovarian cancer, especially in patients with germline or somatic BRCA mutations or other homologous recombination deficiency (HRD). With high efficacy and costs, insurers may enact barriers or facilitators to PARP-I. Our objective was to examin...

Full description

Bibliographic Details
Main Authors: Anna Jo Bodurtha Smith, Annie Apple, Audra Hugo, Ashley Haggerty, Emily M. Ko
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Gynecologic Oncology Reports
Subjects:
Insurance
Medicare
Medicaid
Ovarian cancer
PARP inhibitors
Prior Authorization
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578924000146

Internet

http://www.sciencedirect.com/science/article/pii/S2352578924000146

Similar Items